Загрузка...
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patien...
Сохранить в:
| Опубликовано в: : | Ther Adv Med Oncol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535754/ https://ncbi.nlm.nih.gov/pubmed/31205507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919849753 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|